Novel immunotherapeutic strategies for colorectal cancer treatment: Advances, challenges, and future directions.
Immunotherapy benefits extend beyond the traditionally responsive group, offering hope to more colorectal cancer patients than previously recognized.
Immunotherapy has reshaped the treatment landscape of colorectal cancer (CRC), with the clearest and most durable benefit established in mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) disease. However, framing CRC immunotherapy simply as "MSI-H responsive versus microsatellite stable (MSS) resistant" is no longer sufficient.
What the study was
- Study design
- Observational/Descriptive
- Population
- Adult patients
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Biochimica et biophysica acta. Reviews on cancer
Why it surfaced
Score 7/10: Observational/Descriptive, mixed model, Exploratory; flag=EARLY_CANCER_DETECTION
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.